In vitro activity of Tachyplesin III alone and in combination with terbinafine against clinical isolates of dermatophytes

Peptides

Volumn 30, Issue 10, 2009, Pages 1794-1797

  Simonetti, O ^a   Ganzetti, G ^a   Arzeni, D ^a   Campanati, A ^a   Marconi, B ^a   Silvestri, C ^a   Cirioni, O ^a   Gabrielli, E ^a   Lenci, I ^a   Kamysz, W ^b   Kamysz, E ^c   Giacometti, A ^a   Scalise, G ^a   Barchiesi, F ^a   Offidani, A ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c UNIVERSITY OF GDA SK   (Poland)

Author keywords

Dermatophytes; Fungal biomass; Sinergy testing; Tachyplesin III; Terbinafine

Indexed keywords

TACHYPLESIN; TACHYPLESIN III; TERBINAFINE; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ARTICLE; BROTH DILUTION; CONTROLLED STUDY; DERMATOPHYTE; DRUG IDENTIFICATION; DRUG POTENTIATION; FUNGAL BIOMASS; FUNGUS ISOLATION; IN VITRO STUDY; MICROSPORUM CANIS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; SPECIES DIFFERENCE; TRICHOPHYTON MENTAGROPHYTES; TRICHOPHYTON RUBRUM;

AMINO ACID SEQUENCE; ANTI-INFECTIVE AGENTS; ANTIFUNGAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; ARTHRODERMATACEAE; DERMATOMYCOSES; DNA-BINDING PROTEINS; DRUG SYNERGISM; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; NAPHTHALENES; PEPTIDES, CYCLIC;

ARTHRODERMA BENHAMIAE; ARTHRODERMATACEAE; MICROSPORUM CANIS; TRICHOPHYTON RUBRUM;

EID: 70349330507     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2009.06.033     Document Type: Article

References (20)

1. Alió A.B., Mendoza M., Zambrano E.A., Díaz E., and Cavallera E. Dermatophytes growth curve and in vitro susceptibility test: a broth micro-titration method. Med Mycol 43 (2005) 319-325
2. Barchiesi F., Silvestri C., Arzeni D., Ganzetti G., Castelletti S., Simonetti O., et al. In vitro susceptibility of dermatophytes to conventional and alternative antifungal agents. Med Mycol 47 (2009) 321-326
3. Debruyne D., and Coquerel A. Pharmacokinetics of antifungal agents in onychomycoses. Clin Pharmacokinet 40 (2001) 441-472
4. Denning D.W., Hanson L.H., Perlman A.M., and Stevens D.A. In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diag Microbiol Infect Dis 15 (1992) 21-34
5. Fernández-torres B., Vázquez-veiga H., Llovo X., Pereiro Jr. M., and Guarro J. In vitro susceptibility to itraconazole, clotrimazole, ketoconazole and terinafine of 100 isolates of Trichophyton rubrum. Chemotherapy 46 (2000) 390-394
6. Galgóczy L., Papp T., Pócsi I., Hegedus N., and Vágvölgyi C. In vitro activity of Penicillium chrysogenum antifungal protein (PAF) and its combination with fluconazole against different dermatophytes. Anton Leeuw Int J G 94 (2008) 463-470
7. Gupta A.K., and Kohli Y. In vitro susceptibility testing of ciclopirox, terbinafine, ketokonazole and intraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity. Br J Dermatol 149 (2003) 296-305
8. Hancock R.E.W., and Chappel D.S. Peptides antibiotics. Antimicrob Agent Chemother 43 (1999) 1317-1323
9. Hancock R.E.W., and Sahl H.G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 24 (2006) 1551-1557
10. Kawano K., Yoneya T., Miyata T., Yoshikawa K., Tokunaga F., Terada Y., et al. Antimicrobial peptide Tachyplesin I isolated from hemocytes of the horseshoe crab (Tachypleus tridentatus). J Biol Chem 265 (1990) 15365-15367
11. Meinhof W. Kinetics and spectrum of activity of oral antifungals: the therapeutic implications. J Am Acad Dermatol 29 (1993) S37-S41
12. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard. NCCLS document M38-A. National Committee for Clinical Laboratory Standards, Wayne, PA. 2003.
13. Nakamura T., Furunaka H., Miyata T., Tokunaga F., Muta T., Iwanaga S., et al. Tachyplesin, a class of antimicrobial peptide from the hemocytes of the horseshoe crab (Tachypleus tridentatus). Isolation and chemical structure. J Biol Chem 263 (1998) 16709-16713
14. Niewerth M., and Korting H.C. The use of systemic antimycotics in dermatotherapy. Eur J Dermatol 10 (2000) 155-160
15. Rao A.G. Conformation and antimicrobial activity of linear derivatives of Tachyplesin lacking disulfide bonds. Arch Biochem Biophys 361 (1999) 127-134
16. Santos D.A., Barros M.E.S., and Hadan J.S. Establishing method of inoculum preparation for susceptibility testing of Trichophyton rubrum and Trichophton mentagrophytes. J Clin Microbiol 44 (2006) 98-101
17. 2), alone and in combination with antifungal agents, against clinical isolates of dermatophytes. Br J Dermatol (2009) 1-4
18. Xu F., Meng K., Yang Y.R., Luo H.Y., Yang P.L., et al. Eukaryotic expression and antimicrobial spectrum determination of the peptide Tachyplesin II. Protein Expr Purif 58 (2008) 175-183
19. Yeaman M.R., and Yount N.Y. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev 55 (2003) 27-55
20. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 415 (2002) 389-395